Notably, SOX2 overexpression decreases cisplatin-induced cell apoptosis in lung cancer, while inhibition of SOX2 enhances cisplatin toxicity and promotes apoptosis in A549 and A549/CDDP cells [11], suggesting that SOX2 is a vital regulator of cisplatin resistance in NSCLC. The gene discussed is SOX2; the disease is lung cancer.